What Is a Focal Liver Lesion? Types, Diagnosis & Treatment

A focal liver lesion is any abnormal area of tissue within the liver that stands out from the surrounding healthy liver on imaging. These spots show up with increasing frequency as more people undergo CT scans, MRIs, and ultrasounds for unrelated reasons, and most of them turn out to be harmless. In people without underlying liver disease, the vast majority of incidentally discovered focal liver lesions are benign, even among patients who have a known cancer elsewhere in the body.¹ Still, “benign until proven otherwise” only holds when doctors can confidently tell one type of lesion from another, and that distinction drives the diagnostic workup.

Why Focal Liver Lesions Are Found So Often Now

Decades ago, a liver lesion was usually discovered because a patient had symptoms: pain, jaundice, a palpable mass. Today, the picture is very different. Abdominal imaging has become routine for everything from kidney stones and gallbladder complaints to trauma screening and pre-surgical planning. Each of those scans captures the liver whether that was the point or not, and radiologists are trained to flag anything that looks unusual. The result is a sharp rise in what clinicians call incidental focal liver lesions. One large review defines these as hepatic lesions found in patients imaged for an unrelated reason, and notes they are “frequently encountered in daily practice, sometimes leading to unnecessary, invasive and potentially harmful follow-up investigations.”¹ In low-risk patients under 40 with no history of malignancy or chronic liver disease, over 95% of these incidental findings are benign.

Benign Focal Liver Lesions

Benign lesions fall into two broad families: those that are solid and those that are fluid-filled (cystic). Understanding the common types matters because the management of each one is quite different.

Hemangiomas

Hepatic hemangiomas are the most common benign liver tumors. They are tangles of blood vessels within the liver, and they can be classified as capillary or cavernous types. The exact reason they form is not fully understood, though hormone exposure has been suggested as a factor in their growth. On ultrasound, they tend to appear bright and well-defined. On MRI, cavernous hemangiomas stand out because of high signal intensity on certain sequences, which is one of the most reliable ways to identify them.² The good news is that hemangiomas carry no risk of becoming cancerous, and surgical intervention is not indicated unless they cause progressive symptoms.³

Focal Nodular Hyperplasia

Focal nodular hyperplasia (FNH) is the second most common benign solid liver lesion. It is a well-organized cluster of liver cells, bile ducts, and blood vessels, often with a characteristic central scar visible on imaging. Patients with FNH are usually asymptomatic and rarely experience complications.⁴ Like hemangiomas, FNH has no recorded potential for malignant transformation, so watchful observation is the standard approach.³ Many FNH lesions are discovered by accident and never require treatment at all.

Hepatocellular Adenomas

Hepatocellular adenomas are rarer and more concerning than hemangiomas or FNH. The most serious complication is bleeding, either inside the tumor or into the abdominal cavity, which occurs in roughly half to 60% of patients.⁴ A subgroup of adenomas also carries a risk of malignant transformation, particularly those with certain genetic features involving a pathway called beta-catenin activation. After an episode of massive hemorrhage, elective treatment may be considered for adenomas larger than 5 cm, given about a 4% risk of re-bleeding.⁵ Because of these risks, adenomas receive closer follow-up than hemangiomas or FNH, and surgery is recommended when symptoms progress or malignancy is suspected.³

Simple Cysts and Cystic Neoplasms

Simple hepatic cysts are fluid-filled sacs lined with a thin layer of cells. They are congenital in most cases, forming from bile ducts that never connected to the main biliary system. They can range from tiny lesions under a centimeter to very large ones up to 30 cm, and they may contain up to two internal dividers (septa).⁶ Simple cysts almost never cause problems and do not need treatment unless they grow large enough to produce discomfort.

A more concerning type of cystic lesion is the biliary cystadenoma, a slow-growing tumor derived from the lining of bile ducts. These are multilocular, meaning they have many internal compartments, and they carry a 20 to 30% risk of transforming into biliary cystadenocarcinoma.⁶ Telling the two apart on imaging alone is difficult. One study found that nearly a third of patients whose CT or MRI was read as biliary cystadenoma actually had simple cysts on pathology, and that mislabeling led some asymptomatic patients to undergo unnecessary surgery.⁷ Certain CT features can help radiologists distinguish between the two, including the location of the lesion, whether it causes nearby bile duct dilation, and the number of other cysts present.⁸

Malignant Focal Liver Lesions

Not all liver lesions are innocent. Malignant lesions fall into two camps: cancers that start in the liver (primary) and cancers that spread to the liver from somewhere else (metastatic).

Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and almost always arises in a liver that is already damaged by cirrhosis, chronic hepatitis B or C, or heavy alcohol use. It develops from the liver’s own cells and tends to look different from benign lesions on contrast-enhanced imaging: HCC typically takes up contrast avidly in the arterial phase and then “washes out” in later phases, a pattern that forms the backbone of diagnostic criteria. Treatment can range from surgical removal or liver transplantation to less invasive options like ablation and embolization.

Cholangiocarcinoma

Cholangiocarcinoma is a cancer of the bile duct lining and is classified by where it arises along the biliary tree: intrahepatic, perihilar, or extrahepatic. It is rarer than HCC but has been increasing in incidence, and it is difficult to catch early because symptoms often do not appear until the tumor is advanced.⁹ Imaging with ultrasound, CT, and MRI all play roles in detecting and staging cholangiocarcinoma, but the intrahepatic form can be particularly tricky to distinguish from other lesions.

Liver Metastases

The liver is one of the most common destinations for cancer that has spread from other organs, especially colorectal, breast, lung, and pancreatic cancers. Metastatic lesions in the liver are actually far more common than primary liver cancers. On MRI, they show hallmark features including ring-like enhancement around their edges and restricted movement of water molecules within the tumor tissue.¹⁰ Identifying liver metastases quickly is critical because it changes the staging and treatment plan for the original cancer.

How Focal Liver Lesions Are Diagnosed

When a lesion is spotted on routine imaging, the next question is always: what is it? Doctors rely on a layered approach, starting with the simplest tools and escalating when needed.

Ultrasound and Contrast-Enhanced Ultrasound

Conventional ultrasound is often the first imaging modality to detect a liver lesion, but it frequently cannot tell benign from malignant on its own. Contrast-enhanced ultrasound (CEUS) adds a layer of information by injecting tiny microbubble agents into the bloodstream. These bubbles allow radiologists to watch, in real time, how blood flows through a lesion. Official guidelines recommend CEUS as a second step after an indeterminate ultrasound finding, particularly because it can often confirm benign lesions like hemangiomas on the spot, avoiding more expensive or invasive tests.¹¹ CEUS is also extremely safe and useful in patients who cannot receive CT contrast or undergo MRI.¹²

CT and MRI

Multi-phase CT scans capture the liver during different stages of contrast flow (arterial, portal venous, and delayed phases), and each phase reveals different characteristics of a lesion. MRI goes a step further. Liver-specific contrast agents are taken up by functioning liver cells and then excreted into the bile ducts, producing a unique “hepatobiliary phase” image. In that phase, normal liver tissue lights up while most malignant lesions do not, because cancer cells lose the ability to handle the contrast agent the way healthy hepatocytes do.¹³ This hepatobiliary phase increases the ability to detect malignant lesions, particularly small ones, though its ability to distinguish between different types of malignancy is less certain.¹⁴ Technical adjustments during the scan, such as increasing the flip angle during the hepatobiliary phase, can further improve detection of small malignant lesions under 10 mm.¹⁵

The LI-RADS System

For patients known to be at risk for liver cancer, such as those with cirrhosis, radiologists use a standardized framework called the Liver Imaging Reporting and Data System, or LI-RADS. It assigns each liver observation a category from LR-1 (definitely benign) through LR-5 (definitely HCC), with intermediate categories for lesions that are probably benign, indeterminate, or probably malignant.¹⁶ The system standardizes language across hospitals and helps treatment teams decide next steps without relying on subjective impressions. In validation studies, the LR-5 category had a sensitivity of about 69% and a specificity of 87% for diagnosing HCC, with most false positives resulting from a rare mixed tumor type that is inherently hard to classify.¹⁷

When Biopsy Becomes Necessary

Many focal liver lesions can be diagnosed confidently with imaging alone, but not all of them. When imaging is inconclusive, or when a definitive tissue diagnosis would change the treatment plan, an image-guided biopsy is the next step. UK guidelines from gastroenterology, radiology, and pathology societies jointly recommend image-guided biopsy for targeting focal lesions, particularly in patients with altered liver anatomy from prior surgery or transplantation. They also note that the risk of biopsy may be higher if the lesion is highly vascular or has a cystic component, because the needle may need to traverse the fluid-filled portion to reach the solid tissue.¹⁸ In practice, biopsy is avoided when a lesion clearly fits a benign pattern on imaging, because sticking a needle into a hemangioma, for instance, carries a bleeding risk without adding useful information.

Pseudolesions and Other Mimics

Not everything that looks like a liver lesion on a scan actually is one. Pseudolesions are areas that mimic tumors on imaging but have no underlying tumor biology. They are caused by quirks in the liver’s blood supply. The liver receives blood from two sources, and when the balance between them shifts locally, patches of tissue can look brighter or darker than their surroundings on contrast-enhanced scans. One common example is a transient hepatic attenuation difference, where a wedge-shaped bright area appears during the arterial phase of a CT scan and can closely resemble a hypervascular tumor.¹⁹

Another type of pseudolesion involves focal fatty infiltration or focal fat sparing. Parts of the liver can accumulate fat unevenly, often in predictable locations like the area near the gallbladder or the back part of a certain liver segment. The reason involves the venous drainage pattern in those areas: veins carrying blood with different insulin concentrations drain into different liver zones, and insulin promotes fat deposition. Where insulin levels are higher, fat accumulates; where they are lower, the liver tissue stays lean. On imaging, these patches of fat or fat-free tissue can look like masses.²⁰ Experienced radiologists recognize these patterns, but in ambiguous cases, follow-up imaging or MRI sequences specifically designed to detect fat can resolve the question without biopsy.

Treatment Approaches for Malignant Lesions

Treatment for malignant focal liver lesions depends on the tumor type, its size and number, and how well the liver is functioning overall.

For early-stage HCC in patients whose liver function is still adequate, surgical removal or liver transplantation offers the best chance of cure. When surgery is not an option, ablation techniques use heat (radiofrequency or microwave energy) delivered through a thin probe to destroy the tumor in place. Embolization, particularly transarterial chemoembolization (TACE), blocks the tumor’s blood supply while delivering chemotherapy directly into the lesion. Combining these two approaches seems to outperform either one alone. A meta-analysis found that patients with HCC larger than 5 cm treated with TACE plus microwave ablation had significantly higher survival rates at one, two, and three years compared to TACE by itself.²¹ Even with combined treatment, smaller lesions respond better: complete local control is substantially higher for tumors under 5 cm than for larger ones.²²

Immune checkpoint inhibitors have recently expanded the toolbox for intermediate and advanced HCC. These drugs help the immune system recognize and attack cancer cells. In some patients, the response is strong enough to downstage tumors to the point where liver transplantation becomes possible. Timing matters, though: a washout period of at least three months between checkpoint inhibitor therapy and transplantation is recommended to reduce the risk of the immune system attacking the new organ. Once transplanted, checkpoint inhibitors should generally be avoided, especially in the early post-transplant period.²³

The Role of Hormones and Steroids

Hormonal exposure is a recurring theme in certain types of focal liver lesions. Oral contraceptives have long been linked to the development of hepatocellular adenomas, and discontinuing them can sometimes cause adenomas to shrink. FNH has also been loosely associated with oral contraceptive use, though the relationship is less clear-cut than with adenomas.

A less widely recognized connection involves anabolic androgenic steroids. Used at supraphysiological doses by bodybuilders and athletes, these drugs are an underrecognized cause of primary liver tumors, particularly adenomas and HCC, arising in young patients who would normally have no reason to develop liver cancer.²⁴ The range of liver damage attributed to anabolic and contraceptive steroids is strikingly broad, from reversible biochemical changes to vascular complications and frank malignancy.²⁵ Because these patients are typically young and otherwise healthy, liver tumors may not be on a clinician’s radar, which can delay diagnosis.

Artificial Intelligence in Liver Lesion Diagnosis

Researchers are beginning to apply machine-learning tools to the problem of ambiguous liver lesions. One approach, called radiomics, extracts quantitative features from CT or MRI images that the human eye cannot easily measure, then feeds them into an algorithm trained to distinguish malignant from benign lesions. In one multicenter study of cirrhotic patients with indeterminate liver nodules, a radiomics signature that analyzed contrast changes between arterial and portal venous phases achieved an area under the curve of about 0.70 in a discovery group and 0.66 in a validation group for identifying HCC.²⁶ Those numbers are moderate rather than game-changing, but the potential lies in using such tools as an additional flag: identifying patients whose nodules deserve closer attention even when traditional imaging criteria are inconclusive. More recent work has focused on aligning AI tools with the LI-RADS framework to ensure their output is clinically actionable and maps onto existing decision pathways.²⁷ This is still an evolving field, and no AI tool has replaced radiologist judgment for liver lesion characterization, but the trajectory suggests these algorithms will increasingly serve as decision-support aids in complex cases.